Galmed Pharmaceuticals (GLMD) PT Set at $14.00 by Maxim Group

Maxim Group set a $14.00 price target on Galmed Pharmaceuticals (NASDAQ:GLMD) in a report published on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on GLMD. ValuEngine cut shares of Galmed Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday, March 28th. Zacks Investment Research cut shares of Galmed Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, January 11th. Finally, HC Wainwright raised their target price on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the company a buy rating in a research note on Monday, February 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock has an average rating of Buy and an average price target of $20.40.

How to Become a New Pot Stock Millionaire

Shares of GLMD traded down $0.07 during mid-day trading on Tuesday, hitting $6.00. 10,036 shares of the company’s stock were exchanged, compared to its average volume of 83,230. Galmed Pharmaceuticals has a 52 week low of $3.61 and a 52 week high of $12.22.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Galmed Pharmaceuticals had a negative return on equity of 133.50% and a negative net margin of 1,133.55%. sell-side analysts expect that Galmed Pharmaceuticals will post -0.77 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in GLMD. Deutsche Bank AG bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter valued at $246,000. Renaissance Technologies LLC bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter valued at $345,000. J. Goldman & Co LP bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter valued at $569,000. Sphera Funds Management LTD. bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter valued at $2,164,000. Finally, Park West Asset Management LLC grew its stake in shares of Galmed Pharmaceuticals by 4.4% in the fourth quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock valued at $2,679,000 after buying an additional 12,347 shares in the last quarter. 18.86% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Galmed Pharmaceuticals (GLMD) PT Set at $14.00 by Maxim Group” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3335701/galmed-pharmaceuticals-glmd-pt-set-at-14-00-by-maxim-group.html.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Favorable News Coverage Somewhat Unlikely to Affect DTS  Stock Price
Somewhat Favorable News Coverage Somewhat Unlikely to Affect DTS Stock Price
Financial Review: Torchmark  and Its Competitors
Financial Review: Torchmark and Its Competitors
TSO3  Sets New 52-Week Low at $0.90
TSO3 Sets New 52-Week Low at $0.90
Net 1 UEPS Technologies  Sets New 12-Month High and Low at $8.62
Net 1 UEPS Technologies Sets New 12-Month High and Low at $8.62
Contrasting LSB Industries  and Praxair
Contrasting LSB Industries and Praxair
Head to Head Survey: American Renal Associates  and Catasys
Head to Head Survey: American Renal Associates and Catasys


© 2006-2018 Ticker Report. Google+.